Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 130,997
  • Shares Outstanding, K 99,998
  • Annual Sales, $ 0 K
  • Annual Income, $ -36,677 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.55
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 13.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.25 +8.80%
on 12/03/25
1.54 -11.69%
on 12/10/25
+0.06 (+4.62%)
since 12/02/25
3-Month
1.24 +9.68%
on 12/01/25
1.93 -29.53%
on 10/22/25
-0.09 (-6.21%)
since 10/02/25
52-Week
1.09 +24.77%
on 04/07/25
2.17 -37.33%
on 07/28/25
-0.61 (-30.96%)
since 01/02/25

Most Recent Stories

More News
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

(December 1, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company advancing anti-inflammatory and

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Stocks in play: Cardiol Therapeutics Inc.

Announces that it has received a Notice of Allowance for the Company's U.S. patent application entitled ...

CRDL.TO : 1.36 (+3.82%)
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRxâ„¢ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRxâ„¢ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

(August 6, 2025) - Cardiol Therapeutics Inc. (NASDAQ:CRDL) (TSX:CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRxâ„¢ over placebo.Reduction in ECV was associated with improvements...

CRDL.TO : 1.36 (+3.82%)
CRDL : 0.9942 (+4.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol...

See More

Key Turning Points

3rd Resistance Point 1.45
2nd Resistance Point 1.41
1st Resistance Point 1.39
Last Price 1.36
1st Support Level 1.33
2nd Support Level 1.29
3rd Support Level 1.27

See More

52-Week High 2.17
Fibonacci 61.8% 1.76
Fibonacci 50% 1.63
Fibonacci 38.2% 1.50
Last Price 1.36
52-Week Low 1.09

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar